FDA approves drug for restless legs syndrome
The United States Food and Drug Administration has approved gabapentin enacarbil (Horizant) extended-release tablets as a once-daily treatment for moderate to severe restless legs syndrome (RLS).
The United States Food and Drug Administration has approved gabapentin enacarbil (Horizant) extended-release tablets as a once-daily treatment for moderate to severe restless legs syndrome (RLS).
Two 12-week clinical trials in adults showed improvement in RLS symptoms in patients taking gabapentin enacarbil compared with placebo. The drug may cause drowsiness and dizziness and can impair the ability to drive or operate complex machinery. It will carry a warning about possible suicidal thoughts and actions similar to the warnings on epilepsy drugs because when gabapentin enacarbil is metabolized it becomes gabapentin, which is used to treat epileptic seizures.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
